2. Academic Validation
  3. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure

Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure

  • Vaccine. 2010 Mar 2;28(10):2161-2168. doi: 10.1016/j.vaccine.2009.12.051.
Sabina H L de Villiers 1,  Nina Lindblom 2,  Genadiy Kalayanov 3,  Sandra Gordon 3,  Ivan Baraznenok 3,  Anna Malmerfelt 2,  Monica M Marcus 2,  Anette M Johansson 3,  Torgny H Svensson 2
Affiliations

Affiliations

  • 1 Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Nanna Svartz väg 2, S-171 77 Stockholm, Sweden. Electronic address: Sabina.de.Villiers@ki.se.
  • 2 Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Nanna Svartz väg 2, S-171 77 Stockholm, Sweden.
  • 3 Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden.
PMID: 20060511 DOI: 10.1016/j.vaccine.2009.12.051
Abstract

The aim of the present study was to synthesise and screen a set of novel nicotine hapten immunogens used for the treatment of nicotine dependence. In the screening process we studied the amount of Antibodies generated and their selectivity, using ELISA techniques, and their effects on nicotine-induced dopamine release in the NAC(shell) of the rat, assessed by in vivo voltammetry. We conclude that even small changes such as the linker attachment on the nicotine molecule as well as the structure of the linker may greatly influence the selectivity of the Antibodies and the central neurobiological effects of nicotine that are considered critical for its dependence producing properties.

Figures
Products